^
    Back
    Association details:
    Biomarker:KRAS G12
    Cancer:Non Small Cell Lung Cancer
    Drug:RMC-6236 (RAS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Excerpt:
    ...- Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing....
    Trial ID:
    NCT05379985
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    Published date:
    10/16/2023
    Excerpt:
    RMC-6236 exhibits promising anti-tumor activity in patients with KRASG12X PDAC and NSCLC at doses that are well tolerated.
    Trial ID:
    NCT05379985